JAK inhibitor for Blau syndrome
Treatments studied
Part of Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a new oral drug that blocks inflammation in people with Blau syndrome, a rare genetic condition causing joint, eye, and skin problems. The goal is to see if the drug can reduce symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of Blau syndrome with arthritis, uveitis, and dermatitis (or a positive biopsy showing granulomas)
- Genetic test shows a mutation in the NOD2 gene
- No other autoimmune diseases (like lupus or rheumatoid arthritis)
- No current cancer (such as lymphoma or leukemia)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the drug tofacitinib (a JAK inhibitor) can help people with Blau syndrome whose symptoms did not improve with other treatments. Blau syndrome is a rare genetic condition that causes inflammation in the skin, joints, eyes, and other organs.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
This trial tests a combination of a steroid (methylprednisolone) and a JAK inhibitor to treat toxic epidermal necrolysis, a severe skin reaction. The goal is to see if adding the JAK inhibitor helps improve outcomes and safety.
This study tests the safety of a daily pill called Tofacitinib for adults with mild-to-moderate Sjögren's disease. It aims to see if this drug helps manage symptoms when other treatments haven't worked well.
This trial tests a new oral medicine (HS-10374) for people with active psoriatic arthritis who have not responded well to standard treatments. It compares the drug to a placebo to see if it reduces joint pain, swelling, and skin symptoms.
This trial tests whether a new class of drugs called JAK inhibitors (which block inflammation signals) is better than a standard treatment (calcineurin inhibitors) for people with lung scarring (interstitial lung disease) caused by Anti-Synthetase Syndrome. It is for people who have not yet taken any immune-suppressing medications for this condition.
Hear when a new Blau Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.